FDA Advisory Committee recommends Probuphine to treat Opiod Dependence
Titan Pharmaceuticals, Inc. has announced that the majority of Psychopharmacologic Drugs Advisory Committee (PDAC) of the FDA members recognized the favorable benefit-risk profile of Probuphine and voted for approval (10 positive votes, 4 negative votes and 1 abstention) in favour of approval.
Probuphine is a long-acting, subdermal implant formulation of buprenorphine for the maintenance treatment of adult patients with Opioid Dependence. In December 2012, Titan announced an exclusive license agreement with Braeburn Pharmaceuticals to the commercialization rights for Probuphine in the United States and Canada.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins